Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb.
Recent Mentions
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Sources
Mentions
Mentions of this stock across all news source scraped in the past 30 days
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
investing.com
22.5%
Fintel
15%
insidermonkey.com
12.5%
Others
50%
•
•
•
•
•
•
•
•
Country
US
Industry
Health Care
Market Cap
Large Cap
Num. Employees
34100
IPO Date
Jul 5, 1929
Country
US
Industry
Health Care
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
News Sentiment
Sentiment
Composite sentiment (positive vs. negative language) expressed across news sources mentioning this stock
Today
Recent Mentions
Recent articles, blogs, and social posts pertaining to this stock
Slightly Bearish
-8.54% more bearish
compared to last week
Related Stocks
Related Stocks
Stocks being mentioned with BMY